AURIGA MEDICAL LAUNCHED Burlington, MA, USA, February 2003 - Auriga Medical which designs, manufactures and delivers high quality radioactive products for use in Brachytherapy, cancer treatment and medical research has been launched. Auriga Medical is the new name for the medical therapy business of QSA, a business owned by UK-based AEA Technology. A key part of Auriga Medical's strategy will be to form strategic alliances with radioimmunotherapy developers within the pharmaceutical industry and position the medical products business among nuclear medicine physicians, radiation therapy specialists and radiopharmacists in Europe, the USA and Asia. The company has significant expertise in the development, production and delivery of high quality radioisotopes, including more than 15 years providing Yttrium-90 chloride for clinical use in cancer treatment. It also provides a unique product design and application consultancy service and calibration program. Patrick Donahue, Director of Medical Therapies at Auriga, said, "This is a very exciting time to be involved in the therapeutic application of radioisotopes. A number of important new targeted radiation therapies have been approved or are under clinical investigation for the treatment of cancer and other diseases. Our goal is to capitalise on our track record in the development of innovative radioactive sources and in reliable supply of Y-90 chloride solution for clinical use. We will focus on our unique capabilities to form strategic alliances with developers of radioimmunotherapy and brachytherapy devices. We have a state-of-the-art manufacturing plant in Braunschweig, Germany and are establishing a distribution centre in the US." Mr Donahue added. Other recent releases to come. Auriga is a star constellation in the Northern Hemisphere, known as the 'the charioteer', it is imbued with the values of speed, delivery, efficiency and accuracy. - Ends - Notes to editors: Auriga Medical AEA Technology is an international market leader in producing high-quality products for industrial, medical, environmental and research applications. Auriga Medical provides a custom design and manufacturing service to develop radioactive products for partners involved in medical research and delivering products to patients. The company currently produces a sealed Sr-90 Brachytherapy source for Novoste Corporation's 3.5F BetaCath system, the market leader in the use of radiation for the reduction of vascular restenosis following cardiac angioplasty. It also draws on AEA Technology QSA's many years of experience in design, development, packaging and worldwide distribution of radioactive products used in a variety of applications. Through its related isotrak family of calibration sources, AEA Technology QSA sets the standard for calibration and measurement of beta-emitting radioisotopes used in many of the new targeted radiotherapy products. Pat Donahue BS, MBA, has over 20 years experience in radioactive products. Prior to joining AEA Technology, he served as Director of Medical Brachytherapy products at Alliant Medical for five years, where he was responsible for development, marketing and sales of radioactive implants for the treatment of prostate cancer. Pat was Associate Director of engineering at DuPont Radiopharmaceuticals for nine years. For further information, or an interview with the Pat Donahue, Director of Medical Therapies, at Auriga Medical, contact:
Debbie Broadhurst or Paul Jarman at Harvard Health
Tel: +44 1932 350006
Fax: +44 1932 353336
Email: dbroadhurst@harvardhealth.co.uk
Pjarman@harvardhealth.co.uk < back
|
